Newstral
Article
Reuters on 2019-11-20 11:34
Trennung von Novartis kommt Augenheilkonzern Alcon teuer zu stehen
Related news
- Augenheilkonzern Alcon rutscht operativ in die roten ZahlenReuters
- Pharmakonzern Novartis treibt Alcon-Börsengang voranReuters
- Struggling Alcon shows some progress as Novartis weighs spinoffStar Telegram
- Novartis open global data center at Alcon in Fort WorthStar Telegram
- Rechtsstreit um Kundengebühren in Hongkong kommt UBS teuer zu stehenReuters
- Novartis Considers Alcon Spin-OffForbes
- Novartis says 'never say never' to Alcon disposalReuters
- Novartis slims down with $25bn spin-off of Alcon eyecare businessbusinessdayonline.com
- Novartis replaces Alcon CEO, restructures its businessbizjournals.com
- Fort Worth’s Alcon spun off Novartis, now trading on NYSEStar Telegram
- Novartis Weighs Spinning Off Alcon Eye-Care Unitwsj.com
- WestLB-Nachfolger Portigon kommt Cum-Ex-Skandal teuer zu stehenReuters
- Novartis launches $5 billion share buyback, mulls Alcon spin-offReuters
- [Audio] Episode 148 -- A Review of the Novartis and Alcon FCPA Enforcement Actionjdsupra.com
- Alcon feiert Mega-Börsendebüt - Eisbrecher in Europa?Reuters
- Neue Medikamente geben Novartis SchwungReuters
- Pharmakonzen Novartis spürt Corona-KriseReuters
- Pharmakonzern Novartis traut sich mehr Betriebsgewinn zuReuters
- KEye Laser Surgery Device Service Market Insights – Growth, Challenges and Future Scope to 2026| Alcon (Novartis), J &J, Zeiss, Valeant, Ziemer Ophthalmic, Avedroksusentinel.com
- Alcon targeted in $110M gender discrimination lawsuitbizjournals.com